Allogene Therapeutics - ALLO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.62
  • Forecasted Upside: 158.81 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$10.67
▼ -0.13 (-1.20%)

This chart shows the closing price for ALLO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Allogene Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALLO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALLO

Analyst Price Target is $27.62
▲ +158.81% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $27.62, with a high forecast of $43.00 and a low forecast of $11.00. The average price target represents a 158.81% upside from the last price of $10.67.

This chart shows the closing price for ALLO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Allogene Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2022JMP SecuritiesReiterated RatingBuy$23.00Low
9/22/2022B. RileyLower TargetBuy$21.00 ➝ $18.00Low
8/23/2022Truist FinancialLower Target$29.00Low
8/10/2022OppenheimerLower TargetOutperform$40.00 ➝ $35.00Low
8/10/2022Raymond JamesDowngradeOutperform ➝ Market PerformLow
7/15/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$9.00 ➝ $32.00Low
6/2/2022Robert W. BairdInitiated CoverageNeutral$11.00High
5/24/2022The Goldman Sachs GroupLower TargetNeutral$12.00 ➝ $9.00Medium
5/5/2022Raymond JamesLower Target$36.00 ➝ $13.00High
4/11/2022JMP SecuritiesReiterated RatingBuy$23.00Low
3/29/2022William BlairReiterated RatingOutperformHigh
3/7/2022The Goldman Sachs GroupLower TargetNeutral$20.00 ➝ $12.00Low
3/4/2022HC WainwrightReiterated RatingBuy$43.00Medium
2/28/2022B. RileyLower TargetBuy$30.00 ➝ $21.00Low
1/11/2022HC WainwrightReiterated RatingBuy$43.00High
1/4/2022GuggenheimLower Target$40.00 ➝ $35.00Low
12/17/2021JMP SecuritiesReiterated RatingBuy$27.00High
12/14/2021Royal Bank of CanadaLower TargetOutperform ➝ Outperform$45.00 ➝ $35.00High
10/20/2021CowenInitiated CoverageOutperformLow
10/12/2021JMP SecuritiesLower TargetHold ➝ Outperform$53.00 ➝ $27.00Low
10/8/2021HC WainwrightReiterated RatingBuy$43.00N/A
10/8/2021Bank of AmericaLower TargetBuy$41.00 ➝ $32.00N/A
10/8/2021Jefferies Financial GroupReiterated RatingBuyN/A
10/8/2021Roth CapitalLower TargetHold ➝ Buy$60.00 ➝ $35.00N/A
10/8/2021Stifel NicolausDowngradeBuy ➝ Hold$44.00 ➝ $18.00N/A
10/8/2021William BlairReiterated RatingBuyN/A
10/8/2021OppenheimerLower TargetOutperform$44.00 ➝ $40.00N/A
10/8/2021Royal Bank of CanadaLower TargetHold ➝ Outperform$55.00 ➝ $45.00N/A
10/8/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$71.00 ➝ $20.00N/A
9/23/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$36.00High
8/6/2021B. RileyLower TargetBuy$52.00 ➝ $40.00High
8/5/2021OppenheimerLower TargetOutperform$52.00 ➝ $44.00High
7/1/2021Jefferies Financial GroupReiterated RatingBuy$53.00Low
6/22/2021Jefferies Financial GroupInitiated CoverageBuy$53.00High
5/20/2021Truist FinancialUpgradeHold ➝ Buy$34.00 ➝ $41.00N/A
5/14/2021B. RileyInitiated CoverageBuy$52.00Medium
4/22/2021HC WainwrightReiterated RatingBuyLow
4/12/2021OppenheimerReiterated RatingBuyHigh
3/1/2021HC WainwrightBoost TargetBuy$40.00 ➝ $43.00Low
1/26/2021Stifel NicolausUpgradeHold ➝ Buy$33.00 ➝ $43.00High
12/14/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
12/10/2020HC WainwrightReiterated RatingBuy$40.00Medium
11/24/2020Bank of AmericaInitiated CoverageBuy$41.00Medium
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$55.00Medium
8/9/2020Jefferies Financial GroupReiterated RatingBuyLow
8/9/2020CowenReiterated RatingBuyLow
8/6/2020HC WainwrightReiterated RatingBuy$49.00Medium
6/12/2020HC WainwrightLower TargetBuy$55.00 ➝ $49.00Medium
6/8/2020SunTrust BanksBoost TargetHold$32.00 ➝ $50.00Low
6/1/2020JMP SecuritiesBoost Target$37.00 ➝ $53.00High
6/1/2020The Goldman Sachs GroupBoost TargetBuy$45.00 ➝ $66.00High
6/1/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
5/31/2020OppenheimerBoost TargetOutperform$50.00 ➝ $55.00Medium
5/29/2020William BlairReiterated RatingBuyLow
5/29/2020HC WainwrightBoost TargetBuy$42.00 ➝ $55.00High
5/29/2020Piper SandlerBoost TargetOverweight$50.00 ➝ $70.00High
5/19/2020Roth CapitalUpgradeNeutral ➝ Buy$26.00 ➝ $60.00Low
5/15/2020GuggenheimUpgradeNeutral ➝ BuyHigh
5/14/2020Jefferies Financial GroupBoost TargetBuy$37.00 ➝ $45.00High
5/14/2020SunTrust BanksDowngradeBuy ➝ Hold$29.00 ➝ $32.00High
5/13/2020HC WainwrightReiterated RatingBuy$35.00 ➝ $42.00High
5/13/2020OppenheimerBoost TargetOutperform$44.00 ➝ $50.00High
5/6/2020OppenheimerInitiated CoverageBuy$44.00Low
4/13/2020SunTrust BanksInitiated CoverageBuy$29.00 ➝ $29.00High
3/24/2020OppenheimerReiterated RatingBuy$44.00High
3/13/2020HC WainwrightInitiated CoverageBuy$35.00High
3/4/2020Stifel NicolausInitiated CoverageHold$27.00Medium
2/24/2020Berenberg BankInitiated CoverageHold$27.00High
12/18/2019JMP SecuritiesInitiated CoverageOutperform$37.00Medium
11/6/2019JPMorgan Chase & Co.Reiterated RatingHold$29.00High
11/5/2019William BlairReiterated RatingBuyHigh
10/10/2019William BlairReiterated RatingBuyLow
8/11/2019JPMorgan Chase & Co.Reiterated RatingHold$29.00High
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$37.00Low
6/5/2019Roth CapitalInitiated CoverageNeutral ➝ Neutral$26.00 ➝ $26.00High
5/30/2019GuggenheimInitiated CoverageNeutralMedium
5/22/2019Stifel NicolausInitiated CoverageHold ➝ Hold$27.00High
5/3/2019OppenheimerInitiated CoverageOutperform$45.00 ➝ $45.00Low
4/15/2019William BlairReiterated RatingBuyLow
3/29/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$50.00High
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$40.00Medium
3/13/2019William BlairInitiated CoverageOutperformLow
3/11/2019JPMorgan Chase & Co.Reiterated RatingHold$29.00Medium
3/8/2019CowenReiterated RatingBuyLow
11/5/2018CowenInitiated CoverageOutperform ➝ OutperformHigh
11/5/2018JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$29.00High
11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$31.00High
11/5/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$41.00High
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/7/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/6/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/6/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
8/5/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/4/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/4/2022

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Allogene Therapeutics logo
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $10.67
Low: $10.61
High: $11.21

50 Day Range

MA: $13.90
Low: $10.32
High: $17.28

52 Week Range

Now: $10.67
Low: $6.43
High: $25.00

Volume

1,120,381 shs

Average Volume

1,843,228 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Allogene Therapeutics?

The following Wall Street analysts have issued research reports on Allogene Therapeutics in the last twelve months: B. Riley, Bank of America Co., Cowen Inc, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Co., and William Blair.
View the latest analyst ratings for ALLO.

What is the current price target for Allogene Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Allogene Therapeutics in the last year. Their average twelve-month price target is $27.62, suggesting a possible upside of 158.8%. HC Wainwright has the highest price target set, predicting ALLO will reach $43.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $11.00 for Allogene Therapeutics in the next year.
View the latest price targets for ALLO.

What is the current consensus analyst rating for Allogene Therapeutics?

Allogene Therapeutics currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALLO will outperform the market and that investors should add to their positions of Allogene Therapeutics.
View the latest ratings for ALLO.

What other companies compete with Allogene Therapeutics?

How do I contact Allogene Therapeutics' investor relations team?

Allogene Therapeutics' physical mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 457-2700 and its investor relations email address is [email protected] The official website for Allogene Therapeutics is www.allogene.com. Learn More about contacing Allogene Therapeutics investor relations.